drugset / Trial / NCT00570986

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00570986

Phase 3 Completed 1465 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.

Timeline

Start
2007-11
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator briakinumab Monoclonal antibody 100 mg

Indications